# Hepatology Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Evel Knievel (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-RB001-SYN
- Date: 2026-01-26
- Fictional facility: St. Posthumous Health Center
- Fictional author: Mei-Ling Okonkwo, MD
- Calendar frame: modern shifted

- Requested by: Dale Rasmussen, MD

## Reason for consultation

Raised transaminases (ALT 88, AST 96 U/L) and platelets of 118 on today's tests, with spider angiomas and palmar erythema, in a 57-year-old retired stunt performer who received many blood transfusions after crashes before 1992, drinks most evenings and has type 2 diabetes. Hepatitis C antibody with reflex RNA, hepatitis A and B serology, HIV and an abdominal ultrasound are ordered. Please see him within three weeks to confirm the cause, stage his liver disease and plan treatment. **S**

## History

Mr. Knievel, 57, is seen at the request of Dr. Rasmussen two weeks after raised transaminases and low platelets were found at his first visit. He received many transfusions after crashes during his stunt career, before blood was screened for hepatitis C. The hepatitis C antibody is positive with HCV RNA 2.35 million IU/mL, genotype 1a; he has never been treated. He drank three or four drinks most evenings and has cut down to about two since the first visit. He has type 2 diabetes on metformin and chronic pain from old fractures; ibuprofen and omeprazole were stopped two weeks ago. He has had no jaundice, abdominal swelling, black stools, vomiting of blood or confusion. **S**

## Examination

| System | Finding |
|---|---|
| General | Well; blood pressure 136/82, pulse 78 |
| Skin | Six spider angiomas; palmar erythema; no jaundice |
| Abdomen | Firm liver edge 2 cm below the costal margin; spleen tip palpable; no shifting dullness |
| Neurological | No asterixis |

BP 136/82 mmHg; pulse 78 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 85.6 kg; BMI 27 kg/m². All vital signs are synthetic.

## Data reviewed

Dr. Rasmussen's intake note and results: platelets 118, ALT 88, AST 96 U/L, bilirubin 1.1 mg/dL, albumin 3.6 g/dL, INR 1.1, creatinine 0.92 mg/dL, eGFR 97, A1c 7.4%, LDL 112 mg/dL; FIB-4 4.94. Serology: HCV RNA 2.35 million IU/mL, genotype 1a; hepatitis B surface antigen, core antibody and surface antibody negative; hepatitis A IgG negative; HIV negative. Ultrasound a week ago: nodular liver, coarse echotexture, no focal lesion, spleen 14.2 cm, patent portal vein with forward flow, no ascites. Transient elastography in clinic today: 26.8 kPa (reliable), controlled attenuation parameter 248 dB/m. Liver stiffness (transient elastography): 26.8 kPa (high); PHQ-9: 6; AUDIT-C: 4; Pain (0 to 10): 6. All results are synthetic.

## Assessment

1. **Chronic hepatitis C, genotype 1a, treatment-naive** (B18.2). Chronic hepatitis C, almost certainly acquired through transfusions. He meets the AASLD-IDSA criteria for simplified treatment of compensated cirrhosis. I recommend sofosbuvir-velpatasvir, one tablet daily for 12 weeks; glecaprevir-pibrentasvir for 8 weeks would also be suitable but interacts strongly with atorvastatin, which he needs. He must not take a proton pump inhibitor during treatment; famotidine up to 40 mg twice a day is acceptable if needed. Hepatitis B tests are negative, so there is no reactivation risk. On-treatment liver tests are optional; glucose should be watched because control can improve quickly as the virus clears. Cure is confirmed by HCV RNA 12 or more weeks after the last dose. **S**
2. **Compensated cirrhosis, Child-Pugh A5, MELD-Na 8** (K74.69). FIB-4 4.94, liver stiffness 26.8 kPa, a nodular liver, splenomegaly and platelets of 118 establish cirrhosis; alcohol has added to the damage. It is compensated: Child-Pugh A5 and MELD-Na 8. He needs liver cancer surveillance by ultrasound with alpha-fetoprotein every six months for life, including after cure. He does not need a transplant evaluation now; I would refer him if he developed ascites, variceal bleeding, encephalopathy or jaundice, or a MELD-Na of 15. Stopping alcohol completely is the most important thing he can do alongside cure. **S**
3. **Clinically significant portal hypertension** (K76.6). Under Baveno VII, a liver stiffness of 25 kPa or more establishes clinically significant portal hypertension. Carvedilol lowers the risk of decompensation, and a patient taking it does not need screening endoscopy for varices, which would not change treatment. Start 6.25 mg daily and raise it to 12.5 mg if systolic pressure stays above 100. Reassess stiffness and platelets a year after cure. **S**
4. **Type 2 diabetes in cirrhosis** (E11.65). Metformin is appropriate in compensated cirrhosis with normal kidney function, provided he stops drinking. The A1c can read falsely low in cirrhosis, so a continuous glucose monitor is better for decisions. A moderate-intensity statin is safe and indicated. **S**
5. **Chronic pain from old fractures** (G89.29). Keep acetaminophen at or below 2 g a day; avoid oral NSAIDs, which can cause kidney injury, bleeding and fluid retention in cirrhosis; topical diclofenac on small areas is reasonable; avoid opioids, which can precipitate encephalopathy and falls; physical and aquatic therapy are the mainstay. His many old fractures and liver disease also put him at risk of osteoporosis, and a bone density scan is worthwhile. **S**

## Recommendations

1. Sofosbuvir 400 mg and velpatasvir 100 mg, one tablet daily for 12 weeks, once approved; no proton pump inhibitor during treatment; watch for muscle pain on atorvastatin; glucose monitoring for hypoglycemia.
2. HCV RNA and liver tests 12 or more weeks after the last dose.
3. Carvedilol 6.25 mg daily, raised to 12.5 mg daily if tolerated; no screening endoscopy while he takes it; liver stiffness and platelets a year after cure.
4. Ultrasound with alpha-fetoprotein every six months for life, next in July.
5. Hepatitis A and hepatitis B vaccination now (two doses each); pneumococcal, influenza and zoster vaccines in due course.
6. Complete abstinence from alcohol, with counseling or medicine if needed.
7. Teach the signs of decompensation and refer for transplant evaluation only if decompensation occurs or the MELD-Na reaches 15.
8. Atorvastatin 20 mg daily; metformin continued; continuous glucose monitoring; yearly eye examination.
9. Pain care without oral NSAIDs or opioids: acetaminophen up to 2 g a day, topical diclofenac, physical and aquatic therapy; bone density scan and vitamin D level.

## Strengths and supports

- Engagement in care and meaningful activity **S**

## Communication

Discussed with Dr. Rasmussen, who saw him the same day. The diagnosis, the stage of his liver disease and the plan were explained to Mr. Knievel, who agreed to treatment and to stop drinking. **S**

## Follow-up

Hepatology review at the end of treatment and with liver stiffness a year after cure; Dr. Rasmussen continues primary care, starts carvedilol and the vaccines today, and arranges surveillance. **S**

## Guideline basis

- AASLD-IDSA HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Simplified HCV treatment algorithm for treatment-naive adults with compensated cirrhosis (2023), American Association for the Study of Liver Diseases and Infectious Diseases Society of America
- AASLD-IDSA HCV Guidance: Monitoring patients who are starting HCV treatment, are on treatment, or have completed therapy (2026), American Association for the Study of Liver Diseases and Infectious Diseases Society of America
- EPCLUSA (sofosbuvir and velpatasvir) tablets, prescribing information (2025), U.S. National Library of Medicine, DailyMed (Gilead Sciences label)
- Singal AG, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology 2023;78(6):1922-1965 (PMID 37199193) (2023), American Association for the Study of Liver Diseases
- de Franchis R, et al. Baveno VII - Renewing consensus in portal hypertension. J Hepatol 2022;76(4):959-974 (PMID 35120736) (2022), Baveno VII Faculty (Journal of Hepatology)
- Kaplan DE, et al. AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis. Hepatology 2024;79(5):1180-1211 (PMID 37870298) (2024), American Association for the Study of Liver Diseases
- Biggins SW, et al. Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the AASLD. Hepatology 2021;74(2):1014-1048 (PMID 33942342) (2021), American Association for the Study of Liver Diseases
- Crabb DW, et al. Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the AASLD. Hepatology 2020;71(1):306-333 (PMID 31314133) (2019), American Association for the Study of Liver Diseases
- Rakoski M, Goyal P, Spencer-Safier M, et al. Pain management in patients with cirrhosis. Clin Liver Dis (Hoboken) 2018;11(6):135-140 (PMID 30992804) (2018), American Association for the Study of Liver Diseases (Clinical Liver Disease)
- American Diabetes Association. 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. Diabetes Care 2026;49(Suppl 1):S132-S149 (PMID 41358894) (2026), American Diabetes Association
- Watts NB, et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012;97(6):1802-1822 (PMID 22675062) (2012), Endocrine Society
- Adult Immunization Schedule by Medical Condition and Other Indication (2026), Centers for Disease Control and Prevention
